Australian medical equipment company Anteris (AVR.US) IPO priced at $6.78 per share, aiming to raise $100 million.

Australian artificial heart valve manufacturer Anteris Technologies announced its IPO terms on Monday. The company plans to issue 14.8 million shares at a price of $6.78 per share to raise $100 million. At the proposed price, Anteris Technologies will have a market value of $244 million. The company's stock is currently listed on the Australian Securities Exchange under the code "AVR". The $6.78 pricing is based on its closing price on the ASX on December 5. Anteris is a structural heart company focused on patients with aortic stenosis. Its flagship product, DurAVR transcatheter heart valve (THV) system, consists of a single piece bioprosthetic valve. To date, a total of 73 patients in the United States, Canada, and Europe have received treatment with the DurAVR THV system. The company was founded in 1999 and had revenue of $3 million in the 12 months ending September 30, 2024. The company plans to list on Nasdaq under the stock code "AVR". Anteris submitted its application in secrecy on February 14, 2024. TD Cowen, Barclays, and Cantor Fitzgerald are the joint book-runners for this transaction.